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1442Obesity Does Not Preclude Safe and Effective
Myeloablative Hematopoietic Cell Transplantation
(HCT) for Acute Myelogenous Leukemia (AML) in Adults
Willis H. Navarro,1 Manza-A. Agovi,2 Brent R. Logan,2
Karen Ballen,3 Brian J. Bolwell,4 Haydar Frangoul,5 Vikas Gupta,6
Theresa Hahn,7 Vincent T. Ho,8 Mark Juckett,9
Hillard M. Lazarus,10 Mark R. Litzow,11 Jane L. Liesveld,12 Jan S. Moreb,13
David I. Marks,14 Philip L. McCarthy,7 Marcelo C. Pasquini,2 J. Douglas Rizzo2The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health
outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous
leukemia (AML) who underwent autologous (auto, n 5 373), related donor (RD, n 5 2041), or unrelated
donor (URD, n5 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone mar-
row or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant
Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m2) were defined: underweight\18
kg/m2; normal 18-25 kg/m2; overweight .25-30 kg/m2; and obese .30 kg/m2. Multivariable analysis refer-
enced to the normal weight group showed an increased risk of death for underweight patients in the RD
group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P5 .002), but not in the URD group.
There were no other differences in outcomes among the other weight groups within the other HCT groups.
Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not trans-
late into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse out-
comes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone
should not be considered a barrier to HCT.
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Obesity remains an increasingly prominent and
challenging international health issue, particularly in
the developed world [1-7]. Excessive adiposity has been
associated with a number of medical complications,
including cardiovascular disease and diabetes, that
could have an adverse impact on outcomes of
hematopoietic cell transplantation (HCT) for acute
myelogenous leukemia (AML) [6,8,9]. AML is often
optimally treated with HCT, and in some cases,
affords the best opportunity for long-term disease-free
survival (DFS). Recently, it was demonstrated that
even in the intermediate-risk setting, allogeneic HCT
(alloHCT) improves overall survival (OS) compared to
other approaches [10]. However, there has been concern
that obese and overweight patients may not have equiv-
alent outcomes when compared to those of normal
weight. To date, transplant outcomes for patients with
AML based on body mass index (BMI) have not been
well characterized.
Biol Blood Marrow Transplant 16:1442-1450, 2010 1443Obesity in AML AdultsIn 2006, we published results from an observational
study performed by the Center for International Blood
and Marrow Transplantation Research (CIBMTR) for
patients undergoing autologous HCT (autoHCT) for
lymphoma [11]. In that study, we showed that obese pa-
tients fared at least as well as patients with normal BMI.
The purpose of this study was to explore the impact of
BMI in a different disease setting and in the context of
allogeneic transplantation to understand if the previous
observations regarding obesity apply.PATIENTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP), established in 2004, which comprises a vol-
untary working group of more than 450 transplanta-
tion centers worldwide that contribute detailed data
on consecutive allogeneic and autologous hematopoi-
etic stem cell transplantation (SCT) to a Statistical
Center at the Medical College of Wisconsin in Mil-
waukee and the NMDP Coordinating Center in Min-
neapolis. Participating centers are required to report
all transplants consecutively; compliance is monitored
by on-site audits. Patients are followed longitudinally,
with yearly follow-up. Computerized checks for dis-
crepancies, physicians’ review of submitted data, and
on-site audits of participating centers ensure data qual-
ity. Observational studies conducted by the CIBMTR
are performed in compliance with the Privacy Rule
(HIPAA) as a Public Health Authority, and in compli-
ance with all applicable federal regulations pertaining
to the protection of human research participants as de-
termined by continual review of the institutional re-
view boards of the National Marrow Donor Program
and the Medical College of Wisconsin since 1985.Patients
Our study inclusion criteria included all patients
with AML who received a first allogeneic bone mar-
row or peripheral blood stem cell graft HCT from a re-
lated donor (RD alloHCT) or an unrelated donor
(URD alloHCT) or received an autoHCT between
1995 and 2004 and reported to the CIBMTR. Patients
whose transplant center reported myeloablative condi-
tioning (as determined by the transplant center) and
whose disease status prior to transplant was reported
as primary induction failure (PIF), first or second com-
plete remission (CR1, CR2) or first relapse were in-
cluded in this study. For the autologous cohort,
recipients of purged grafts (n 5 55) were excluded. A
total of 4735 patients met these initial selectioncriteria. We further excluded 520 patients (74 autolo-
gous; 305 RD, 141 URD) from teams with inadequate
follow-up or inconsistent reporting over the study pe-
riod to reduce selection and reporting bias of patients.
To ensure that the research patients were representa-
tive of all registered patients in the CIBMTR database,
demographics, relapse, and survival rates between re-
search and registered patients were compared and no
differences were noted.
The final study population included 1801 and 2041
patients who received an URDalloHCT or RDal-
loHCT, respectively, and 373 patients who underwent
autoHCT. Patients were divided into groups based on
BMI calculated from weight at the time of transplanta-
tion. Weight groups were defined according to con-
sensus weight designations by the World Health
Organization [12] and the National Heart Lung and
Blood Institute Expert Panel [13] as follows: under-
weight, BMI\18 kg/m2; normal, BMI 18 to 25 kg/
m2; overweight, BMI .25 to 30 kg/m2; and obese,
BMI .30 kg/m2. Obese (BMI .30-34) and morbidly
obese groups (BMI$35) were combined for all analy-
ses after confirmation of the lack of significant out-
comes differences when analyzed separately (see
section on OS-multivariate analysis for details).
Data Collection
All missing or inconsistent data at the time of data
file preparation were queried. Unavailable data from
the transplant centers was treated as missing in the
analysis. Cytogenetic data at the time of diagnosis or
prior to transplantation were queried if not previously
reported. Cytogenetic data were available for 79% of
patients. Follow-up was updated for all patients in
the data file. The median follow-up by transplant
type and the completeness of follow-up index at 3 years
[14] were 74 months and 94% for RD alloHCT, 58
months and 86% for URD alloHCT, and 85 months
and 80% for auto HCT, respectively.
Study Endpoints
Primary endpoints were OS, treatment-related
mortality (TRM), relapse, and leukemia-free survival
(LFS). OS was defined as time to death from any cause;
surviving patients were censored at time of last follow-
up. TRM was defined as death within the first 28 days
of transplantation from any cause or death in continu-
ous CR at any subsequent time point. Relapse was de-
fined as the time to onset of clinical or hematologic
recurrence, disease progression, or persistent disease.
For relapse, patients with persistent disease were con-
sidered events at day 28. LFS was defined as survival in
continuous CR of primary disease; disease relapse or
persistence or deaths were considered as events.
Secondary endpoints studied included rates of
primary neutrophil and platelet engraftment, grade
Table 1. Characteristics of Patients aged $18 Years, Who Underwent a Myeloablative Bone Marrow or Peripheral Blood Trans-
plantation for AML, Reported to the CIBMTR between 1995 and 2004
Characteristics of Patients Total N (%) Underweight N (%) Normal N (%) Overweight N (%)
Obese/Morbidly
Obese (N %) P-Value‡
Autologous
Number of patients 373 — 169 119 85
Age, median (range), years 46 (18-71) — 42 (18-71) 50 (19-71) 49 (18-70) .001
Male sex 183 (49) — 74 (43) 73 (61) 36 (42) .005
Karnofsky score $90 285 (76) — 128 (76) 92 (77) 65 (77) .989
Disease status at transplant — .069
PIF/first relapse 27 ( 7) — 14 (8) 9 (8) 4 (5)
CR1 247 (68) — 122 (74) 68 (59) 57 (67)
CR2 92 (25) — 30 (18) 38 (33) 24 (28)
Cytogenetics — .049
Favorable risk 66 (18) — 33 (20) 16 (13) 17 (20)
Intermediate risk 204 (54) — 83 (49) 75 (63) 46 (55)
High risk 30 ( 8) — 15 (9) 6 (5) 9 (11)
Unknown* 73 (20) — 38 (22) 22 (18) 13 (15)
Peripheral blood graft 308 (83) — 141 (83) 95 (80) 72 (85)
Total-body irradiation (TBI) 98 (97) — 47 (94) 31 (100) 20 (100) .206
Lung shielding for TBI 24 ( 6) — 9 (5) 8 (7) 7 (8) .663
Year of transplant — .045
1995-1999 271 (73) — 130 (77) 88 (74) 53 (62)
2000-2004 102 (27) — 39 (23) 31 (26) 32 (38)
Median follow-up (range), months 85 (3-148) — 87 (3-148) 80 (8-139) 72 (12-137)
HLA-match sibling donor allogeneic
Number of patients 2041 32 1178 552 279
Age, median (range), years 39 (19-67) 36 (19-54) 37 (18-67) 43 (18-67) 43 (18-64) <.001
Male sex 1065 (52) 13 (41) 603 (51) 323 (59) 126 (45) .001
Karnofsky score $90 1398 (69) 19 (59) 811 (69) 389 (70) 179 (64) .353
Disease status at transplant <.001
PIF/first relapse 572 (28) 12 (38) 322 (27) 744 (26) 94 (34)
CR1 1172 (57) 11 (34) 693 (59) 331 (60) 137 (49)
CR2 297 (15) 9 (28) 163 (14) 77 (14) 48 (17)
AML cytogenetics .327
Favorable risk 223 (11) 3 (9) 132 (11) 56 (10) 32 (11)
Intermediate risk 1078 (53) 15 (47) 614 (52) 290 (53) 159 (57)
High risk 275 (13) 8 (25) 158 (13) 79 (14) 30 (11)
Unknown* 465 (23) 6 (19) 274 (23) 127 (23) 58 (21)
Year of transplant .124
1995-1999 1300 (64) 17 (53) 769 (65) 350 (63) 164 (59)
2000-2004 741 (36) 15 (47) 409 (35) 202 (37) 115 (41)
Bone marrow graft 1004 (49) 12 (38) 605 (51) 262 (47) 125 (45)
Total-body irradiation (TBI) 873 (98) 12 (100) 522 (98) 231 (98) 108 (97) .851
Lung shielding for TBI 506 (25) 9 (28) 328 (28) 115 (21) 54 (19) .001
GVHD prophylaxis .084
T cell depletion 105 (5) — 56 ( 5) 31 ( 6) 18 ( 6)
CNI + MTX ± other 1555 (76) 24 (75) 904 (77) 427 (77) 200 (72)
Other 381 (19) 8 (25) 218 (18) 94 (17) 61 (22)
Median follow-up (range), months 74 (2-152) 83 (24-142) 74 (2-152) 81 (3-149) 73 (3-152)
Unrelated donor allogeneic
Number of patients 1801 33 864 529 375
Age, median (range), years 40 (18-70) 26 (18-52) 37 (18-65) 42 (18-70) 42 (19-68) <.001
Male sex 954 (53) 14 (42) 430 (50) 320 (60) 190 (51) <.001
Karnofsky score $90 1102 (61) 14 (42) 520 (60) 339 (64) 229 (61) .008
Disease status at transplant <.001
PIF/first relapse 729 (41) 14 (42) 368 (43) 421 (40) 133 (36)
CR1 549 (30) 14 (42) 268 (31) 172 (33) 95 (25)
CR2 523 (29) 5 (15) 228 (26) 143 (27) 147 (39)
Cytogenetics at diagnosis .020
Favorable risk 191 (11) 3 (9) 88 (10) 40 (8) 60 (16)
Intermediate risk 897 (50) 17 (51) 438 (51) 275 (52) 167 (47)
Unfavorable risk 378 (21) 9 (27) 188 (22) 111 (21) 70 (19)
Unknown* 335 (19) 4 (12) 150 (17) 103 (19) 78 (21)
Year of transplant .074
1995-1999 747 (41) 16 (48) 383 (44) 205 (39) 143 (38)
2000-2004 1054 (59) 17 (52) 481 (56) 324 (61) 232 (62)
Unrelated Donor Allogeneic
Bone marrow graft 1295 (72) 25 (76) 629 (73) 383 (72) 258 (69)
TBI conditioning 150 ( 8) 7 (21) 83 (10) 45 ( 9) 15 ( 4) .040
Lung shielding for TBI 150 ( 8) 7 (21) 83 (10) 45 ( 9) 15 ( 4) <.001
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Table 1. (Continued )
Characteristics of Patients Total N (%) Underweight N (%) Normal N (%) Overweight N (%)
Obese/Morbidly
Obese (N %) P-Value‡
GVHD prophylaxis .247
T cell depletion 227 (13) 3 ( 9) 101 (12) 62 (12) 61 (16)
CNI + MTX ± other 1359 (75) 30 (91) 664 (77) 400 (76) 265 (71)
Other 215 (12) — 99 (11) 67 (12) 49 (13)
HLA match status† <.001
Well matched 699 (39) 6 (18) 314 (36) 202 (38) 177 (47)
Partially matched 643 (36) 14 (42) 315 (36) 193 (36) 121 (32)
Mismatched 297 (16) 5 (15) 143 (17) 86 (16) 63 (17)
Missing HLA data 162 ( 9) 8 (24) 92 (11) 48 ( 9) 14 ( 4)
Median follow-up (range), months 58 (3-149) 57 (31-119) 60 (4-149) 54 (4-146) 51 (3-136)
HLA indicates human leukocyte antigen; GVHD, graft-versus-host disease; AML, acute myelogenous leukemia; TBI, total body irradiation; CNI, calci-
neurin inhibitors; MTX, methotrexate; PIF, primary induction failure; CR1, first complete remission; CR2, second complete remission.
*Unknown cytogenetics includes patients not tested for cytogenetics, patients that have insufficient cytogenetic information to categorize, or patients
that have non-evaluable metaphases.
†HLAMatch status: well matchedwas defined as no known disparity at HLA -A, -B, -C, -DRB1, partially matched as 1 locus known or likely disparity with
their donors, and mismatched as $2 locus disparity.
‡Chi-square P-value was calculated for categoric values.
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chronic GVHD (cGVHD). Neutrophil engraftment
was defined as the time to achieve a sustained absolute
neutrophil count $500 cells/mL for 3 consecutive
days. Time to platelet engraftment was defined as
time to achieve a platelet count of 20,000/mL, evalu-
able at 7 days from the last platelet transfusion.
aGVHD and cGVHD were graded by the trans-
plant center according to standard criteria [15,16].
Statistical Analysis
Patient-, disease-, and transplant-related factors
were compared among the 4 BMI groups by using
the Chi-squared test for categoric variables and the
Kruskal-Wallis test for continuous variables. Univari-
ate probabilities of LFS and OS were estimated by us-
ing the Kaplan-Meier method [17]. The log rank test
was used for comparing survival curves. Probabilities
of TRM, relapse, neutrophil engraftment, platelet
engraftment, aGVHD, and cGVHD were estimated
by using cumulative incidence to allow for competing
risks. In the multivariate analyses we used Cox propor-
tional hazards regression models separately for each
donor type. Models were constructed to compare the
outcomes among the 4 BMI groups, with normal
BMI used as the baseline group, while adjusting for
all covariates listed in the demographics tables
(Table 1). A model was built for each primary outcome
of interest as a dependent variable and all the relevant
exposure variables as explanatory variables. A main
effect term for the 4 BMI groups was forced into the
model. The proportional hazards assumption for all
the variables was examined by using time-varying
covariates, but violations of this assumption were not
detected. Interactions between weight groups and
other significant explanatory variables were explored,
but none were found significant. The models were
adjusted for the geographical region of the patient(United States, Canada, Europe, Asia, Australia/New
Zealand, Mideast/Africa, and Central/South America)
using a stratified Cox model to account for imbalances
in the BMI groups by region. Bonferroni corrections
were applied to allow adjustment for multiple compar-
isons between each weight group and the normal
weight group. A value of P\ .0167 was therefore con-
sidered statistically significant, whereas the P values for
inclusion in the final models of all other potentially
confounding covariates were set at\.05. Comparisons
of all secondary outcomes were limited to univariate
comparisons.RESULTS
Patient Characteristics
Patients included in this analysis were aged 18
years or older, with AML in first or second CR, in first
relapse, or with PIF after initial therapy, who under-
went HCT between 1995 and 2004, inclusive. A total
of 4215 patients were evaluated in this study. Compar-
isons of patient-, disease-, and transplant-related char-
acteristics among the weight groups are listed in Table
1. Because of low numbers of patients in the under-
weight arm for those undergoing autoHCT (n 5 5),
this group was omitted from analysis. With respect
to the key risk characteristics of age, Karnofsky perfor-
mance status (KPS)\90, disease status at transplant,
cytogenetic risk group, and, for unrelated allogeneic
transplants, donor matching, no differences among
the normal weight, overweight, and obese groups
were observed. For the underweight group, there
were some differences compared to the normal weight
group for the RD alloHCT group (more PIF and first
relapses: 38% versus 28%, respectively) and for
the URD alloHCT group (median age: 26 years
versus 40 years; KPS \90: 58% versus 32%; and
Table 2. Univariate Probabilities of Patients $18 Years of Age Who Received a Myeloablative Bone Marrow or Peripheral Blood
Transplantation for AML, from a Related Donor, Reported to the CIBMTR between 1995 and 2004
Outcome Event Total N (Eval) Underweight Normal Overweight Obese/Morbidly Obese P-Value*
Autologous
Transplant-related mortality† 364
@ 1 year — 5 (2-9) % 4 (1-9) % 5 (1-11) % .973
@ 3 years — 6 (3-10) % 6 (3-11) % 6 (2-13) % .998
Relapse† 364
@ 1 year — 36 (29-44) % 45 (36-54) % 38 (28-49) % .341
@ 3 years — 46 (38-54) % 53 (44-62) % 47 (36-58) % .506
Neutrophil recovery† 365
@ 60 days — 96 (92-99) % 98 (95-100)% 95 (90-99) % .417
Platelet engraftment† 357
@ 100 days — 78 (72-84) % 83 (75-89) % 86 (77-92) % .345
Related donor allogeneic
Transplant-related mortality† 2008
@ 1 year 29 (15-46) % 17 (15 -19) % 21 (18-25) % 25 (16-31) % .007
@ 3 years 29 (15-46) % 21 (18-23) % 25 (22-29) % 30 (24-35) % .010
Relapse† 2008
@ 1 year 39 (23-56) % 24 (21-26) % 22 (18-25) % 26 (21-31) % .214
@ 3 years 42 (25-59) % 30 (27-32) % 27 (23-31) % 31(26-37) % .288
Neutrophil engraftment† 2026
@ 60 days 94 (83-99) % 96 (95-97) % 95 (94-97) % 96 (93-98) % .916
Platelet engraftment† 1962
@ 100 days 72 (55-86) % 86 (84-88) % 82 (79-86) % 79 (74-84) % .011
Chronic GVHD†
@ 1 year 19 (7-34) % 36 (34-39) % 36 (32-40) % 32 (27-38) % .053
Acute GVHD†
Grades 2-4 @100 days 1953 16 (6-31) % 29 (27-32) % 34 (30-38) % 36 (30-42) % .007
Unrelated donor allogeneic
Transplant-related mortality† 1779
@ 1 year 22 (10-38) % 32 (28-35) % 35 (31-39) % 43 (38-48) % .001
@ 3 years 28 (14-45) % 36 (32-39) % 40 (35-44) % 46 (41-51) % .003
Relapse† 1779
@ 1 year 31 (17-48) % 31 (28-34) % 26 (23-30) % 22 (18-27) % .010
@ 3 years 44 (27-61) % 36 (33-39) % 31 (27-35) % 25 (21-29) % <.001
Neutrophil engraftment† 1797
@ 60 days 97 (85-100) % 91 (89-93) % 91 (88-93) % 91 (88-94) % .520
Platelet engraftment† 1768
@ 100 days 67 (50-82) % 69 (66-72) % 69 (65-73) % 65 (61-70) % .668
Chronic GVHD† 1787
@ 1 year 38 (22-55) % 32 (29-36) % 36 (32-41) % 34 (29-38) % .502
Acute GVHD† 1773
Grades II-IV @100 days 48 (31-66) % 44 (41-47) % 46 (42-50) % 50 (45-55) % .228
GVHD indicates graft-versus-host disease; AML, acute myelogenous leukemia.
*Point-wise P-value unless otherwise noted.
†Probabilities of relapse, treatment-related mortality, engraftment, and GVHD were calculated using the cumulative incidence.
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tively). Table 2 summarizes the rates of neutrophil
and platelet engraftment according to BMI group
and transplant type. Hematopoietic recovery was sim-
ilar among all BMI groups.
OS-Univariate Analysis
Figure 1-3 show Kaplan-Meier estimates of OS by
transplant type and weight group. For the RD
alloHCT group, probabilities of OS in the univariate
analysis were similar between the normal (63%; 95%
confidence interval [CI], 60%-66%), and overweight
(60%; 95% CI, 56%- 64%) groups, slightly worse in
the obese group (52%; 95% CI, 47%-58%), and mark-
edly worse in the underweight group (38%; 95% CI,
22%-55%) at 1 year. Corresponding OS probabilities
at 5 years were 47% (95% CI, 44%-50%), 44% (95%
CI, 40%-49%), 37% (95% CI, 31%-43%), and 19%(95%CI, 6%-35%), respectively. For the URD
alloHCT and the autoHCT groups, there were no
statistically significant differences among the weight
groups.
OS-Multivariate Analysis
In multivariate analysis (Table 3) in the RD al-
loHCT setting, with normal weight patients as the ref-
erence, the underweight group had a higher risk of
mortality (RR, 1.92; 95% CI, 1.28-2.89; P 5 .002);
there were no differences among the normal, over-
weight, and obese groups. The morbidly obese group
(BMI $35) was analyzed separately for OS versus the
normal weight group: RD group n 5 118, RR 5
1.05 (0.81-1.35), P 5 .733; URD group: n 5 170,
RR5 1.11 (0.91-1.35), P5 .317. Other factors associ-
ated with higher risks of mortality were age.50 years,
KPS \90%, and disease stage worse than first
Figure 1. (A) Adjusted probability of OS among BMI groups for patients ($18 years) after an RD alloHCT for AML between 1995 and 2004. (B) Ad-
justed probability of DFS among BMI groups for patients ($18 years) after an RD alloHCT for AML between 1995 and 2004.
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depletion for GVHD prophylaxis CsA/methotrexate
[MTX] as the reference group); high-risk cytogenetics
(normal cytogenetics as reference); and use of total
body irradiation (TBI). For the URD alloHCT and
autoHCT groups, there were no differences in OS
among the weight groups.
TRM
Point-wise probabilities of TRM are summarized
in Table 2. In multivariable analysis in the RD al-
loHCT setting, the underweight group experienced
a relative risk (RR) of TRM of 2.23 (95% CI: 1.17-
4.25; P5 .014) compared to the normal weight group.
There were no differences among the other weight
groups. Other significant variables increasing the risk
of TRM were age .40 years, KPS\90, GVHD pro-
phylaxis with CsA 6 other or T cell depletion, and
a disease status of PIF at transplant. A favorable factor
was year of transplant between 2000 and 2004 (versus
1995 to1999). In the URD alloHCT and autoHCT
settings, there were no differences among the BMI
groups.
Relapse
Table 2 summarizes the univariate probabilities of
leukemia relapse by BMI group at each transplant type.
In multivariate analysis, in the RD alloHCT setting,
the underweight group had a higher risk of relapse
compared to the normal weight group, with an RR
of 2.06 (95% CI, 1.20-3.54, P 5 .009). There were
no differences in the other weight groups. Interest-
ingly, similar to the previous study of autoHCT for
lymphoma, the relative risk of relapse was reduced
for the URD alloHCT overweight (RR 0.82, 95%
CI 0.68-0.99, P 5 .044) and obese (RR 0.76, 95% CI
0.0.60-0.96, P5 .022) groups, although this difference
did not translate into a survival benefit. There were nodifferences among the weight groups in the autoHCT
group (underweight was excluded, n 5 5).
LFS
In multivariate analysis, LFS was worse in the RD
alloHCT setting for the underweight group (RR 2.07,
95% CI 1.36-3.13, P 5\.001). Otherwise, no other
differences were observed for any other groups in
any other setting.
aGVHD and cGVHD
The rates of aGVHD and cGVHD by transplant
type are summarized in Table 2. No statistically signif-
icant differences were observed among the weight
groups in either allo HCT setting for either type of
GVHD.DISCUSSION
In this contemporary, retrospective, large study in
AML patients, we demonstrated that obesity as defined
by BMI at time of transplantation does not correlate
with worse survival outcomes, but that underweight
recipients of RD allo HCT have shorter survival com-
pared to patients within the normal BMI range. Simi-
lar to our previous study in patients with lymphoma,
the current study demonstrates that obesity does not
appear to represent a significant barrier to successful
HCT for AML.
The impact of obesity on transplant outcomes
remains controversial. The HCT-specific comorbidity
index (HCT-CI) developed by Sorror et al. [19]
included obesity (BMI.35 kg/m2) as 1 of the compo-
nents to predict nonrelapse mortality (NRM) at 2
years. This study included 708 patients in the training
set who underwent allogeneic HCT for several indica-
tions; of these, 2% were obese. The data in this analysis
Table 3. Multivariable Analysis of AML Patients $18 Years of Age Who Received a Bone Marrow or Peripheral Blood Transplant
between 1995 and 2004, Reported to the CIBMTR
HCT Type Normal Underweight Overweight Obese Overall P-Value
Autologous n 5 164 n 5 5 n 5 112 n 5 81
Death — 0.98 (0.70-1.38) 0.89 (0.61-1.29) Poverall 5 .809
(P 5 .925) (P 5 .532)
Treatment failure — 0.98 (0.70-1.38) 0.12 (0.78-1.59) Poverall 5 .768
(P 5 .919) (P 5 .542)
Relapse — 1.11 (0.76-1.62) 1.19 (0.81-1.75) Poverall 5 .649
(P 5 .574) (P 5 .363)
TRM — 0.79 (0.33-1.91) 0.97 (0.37-2.52) Poverall 5 .861
(P 5 .606) (P 5 .953)
Related allogeneic n 5 1176 n 5 32 n 5 553 n 5 275
Death 1.92 (1.28-2.89) 1.05 (0.91-1.21) 1.16 (0.97-1.38) Poverall 5 .008
(P 5 .002) (P 5 .532) (P 5 .109)
Treatment failure 2.07 (1.36-3.13) 0.97 (0.84-1.12) 1.09 (0.91-1.31) Poverall 5 .005
(P 5 <.001) (P 5 .720) (P 5 .330)
Relapse 2.06 (1.20-3.54) 0.87 (0.71-1.05) 0.96 (0.75-1.23) Poverall 5 .020
(P 5 .009) (P 5 .146) (P 5 .757)
TRM 2.23 (1.17-4.25) 1.12 (0.90-1.38) 1.27 (0.97-1.66) Poverall 5 .040
(p 5 .014) (P 5 .304) (P 5 .081)
Unrelated allogeneic n 5 846 n 5 31 n 5 523 n 5 368
Death 0.86 (0.56-1.33) 0.96 (0.84-1.09) 1.04 (0.89-1.21) Poverall 5 .683
(P 5 .496) (P 5 .502) (P 5 .621)
Treatment failure 0.91 (0.60-1.38) 0.93 (0.82-1.06) 0.99 (0.86-1.15) Poverall 5 .716
(P 5 .652) (P 5 .284) (P 5 .931)
Relapse 1.04 (0.60-1.78) 0.82 (0.68-0.99) 0.76 (0.60-0.96) Poverall 5 .059
(P 5 .893) (P 5 .044) (P 5 .022)
TRM 0.85 (0.44-1.66) 1.03 (0.86-1.24) 1.16 (0.96-1.41) Poverall 5 .439
(P 5 .635) (P 5 .712) (P 5 .129)
— indicates not done due to insufficient number of pts; treatment failure, death or recurrence of disease; AML, acute myelogenous leukemia; TRM,
treatment-related mortality.
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tion initiated by CIBMTR in 2007 so no direct
comparison is possible. However, TRM in our study
was not significantly higher in obese AML patients
compared to normal-weight patients, regardless of
the donor type.
In the previous lymphoma study, we observed
poorer outcomes in 1 of the underweight groups. In-
terestingly, poorer survival outcomes were observed
in underweight patients in the RD allo HCT group
but not the URD alloHCT group. Because of the smallFigure 2. (A) Adjusted probability of OS among BMI groups for patients (
(B) Adjusted probability of DFS among BMI groups for patients ($18 years) anumbers of patients in the RD alloHCT group, there
is some imbalance compared to the other weight
groups with respect to disease status at time of trans-
plantation with disproportionately more PIF/relapse
and CR2 patients, although it is not clear how much
this finding accounts for the difference in LFS and
OS. Such an imbalance of disease status was not seen
in the underweight URD alloHCT group. It is note-
worthy that the underweight RD alloHCT group
had a similar KPS (P 5 .353) and cytogenetic risk
(P5 .327) compared to the other weight groups; these$18 years) after an URD alloHCT for AML between 1995 and 2004.
fter an URD alloHCT for AML between 1995 and 2004.
Figure 3. (A) Adjusted probability of OS among BMI groups for patients ($18 years) after an autologous HCT for AML between 1995 and 2004.
(B) Adjusted probability of DFS among BMI groups for patients ($18 years) after an autologous HCT for AML between 1995 and 2004.
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ference in survival. It may also be that the higher risk of
the URD alloHCT procedure masks important but
less obvious risks associated with being underweight,
whereas in the related donor HCT setting, such risks
become manifest. Small numbers of patients and lack
of available data pertinent to nutritional status such
as serum albumin or TPN use limit the ability to better
characterize this observation in underweight patients.
Moreover, the analysis does not account for unknown
biological factors not included in the model that may
be influencing outcomes in the underweight RD
allo-HCT group.
An important limitation of this study is that any
conditioning regimen dose adjustments for overweight
and obesity used by the various transplant centers
could not be assessed from the CIBMTR data. Because
chemotherapy dosing in the conditioning regimen
may be based on actual weight or adjusted ideal body
weight, clinical outcomes may have been confounded
by whether dose adjustments were made for patients
with high BMI. There is currently no accepted stan-
dard conditioning regimen dose adjustment schema
based on weight and various methodologies are used,
as was ascertained by Grigg and colleagues [20]. A
small study of AML patients undergoing autoHCT
without dose adjustment has previously suggested
that some adjustment may be beneficial, as the
lack of conditioning regimen dose adjustment in that
study resulted in unacceptable treatment-related
mortality [21].
Similar to our previous study in lymphoma, the
current study demonstrates that obesity does not ap-
pear to represent a significant barrier to successful
HCT in AML. This conclusion must be tempered,
however, with the acknowledgment that the patients
who received myeloablative HCT were likely selected
by their transplant centers, and were deemed to be ‘‘fit’’to withstand the rigors of HCT. The limitations of
pretransplant comorbidity data within the CIBMTR
database preclude an assessment of this issue. Thus,
the caveat is that it appears that overweight and obese
patients have similar outcomes to normal-weight pa-
tients when they otherwise appear to be eligible
HCT candidates. Obesity alone, however, should not
preclude HCT when appropriate for the treatment
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